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Summary 
Skeletal complications are a common cause of morbidity in patients with primary bone cancer 
and bone metastases. The type 2 cannabinoid (Cnr2) receptor is implicated in cancer, bone 
metabolism and pain perception. Emerging data have uncovered the role of Cnr2 in the 
regulation of tumour – bone cell interactions and suggest that agents that target Cnr2 in the 
skeleton have potential efficacy in the reduction of skeletal complications associated with 
cancer. This review aims to provide an overview of findings relating to the role of Cnr2 receptor 
in the regulation of skeletal tumour growth, osteolysis and bone pain, and highlights the many 
unanswered questions and unmet needs. This review argues that development and testing of 
peripherally-acting, tumour-, Cnr2-selective ligands in preclinical models of metastatic cancer 
will pave the way for future research that will advance our knowledge about the basic 
mechanism(s) by which the endocannabinoid system regulate cancer metastasis, stimulate the 
development of a safer cannabis-based therapy for the treatment of cancer and provide policy 
makers with powerful tools to assess the science and therapeutic potential of cannabinoid-
based therapy. Thus, offering the prospect of identifying selective Cnr2 ligands, as novel, 
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Preparations of Cannabis Sativa L. plants have been used for medicinal and recreational 
purposes for thousands of years and its constituents are known to modulate a diverse set of 
physiological responses through interaction with the endogenous cannabinoid 
(endocannabinoid) system [1,2]. The endocannabinoid system consists of a family of receptors, 
endogenous ligands and the molecular machinery for their synthesis, transport and metabolism 
(reviewed in [3]). The majority of biological effects associated with cannabinoid receptors are 
mediated by endocannabinoid ligands, plant-derived (phytocannabinoids), and various 
synthetic compounds through their interactions with the classic cannabinoid type 1 (Cnr1) and 
type 2 (Cnr2) receptors albeit with different degrees of selectivity [4,5]. Physiological processes 
associated with the activation of the endocannabinoid system include neurotransmission, pain 
perception, memory and learning, emotions, appetite, motor and endocrine functions, 
cardiovascular homeostasis and immune response (reviewed in [6-10]). There is increasing 
evidence that most members of the endocannabinoid system of ligands, receptors and 
enzymes exert significant effects on tumour cell growth, motility, invasion, spread and 
colonisation of distant organs [6,11,12]. Of relevance to this review is the Cnr2 receptor has 
been detected in bone and cancer cells, and its pharmacological and genetic modulation have 
been shown to influence bone cell activity and bone remodelling in health and in disease. Thus, 
this article focuses on the role of Cnr2 in skeletal tumour growth, osteolytic bone damage and 
bone pain and argues in favour of the notion that therapeutic targeting of the peripheral Cnr2 
may be of value for the reduction of skeletal complications associated with various metastatic 
cancers. 
1. The peripheral Cnr2 receptor  
The CNR2 gene, which encodes the Cnr2 receptor, is located on chromosome 1p36 in human 
[13]. Structurally, Cnr2 shares 44% and 68% amino acid and transmembrane region homology 
with Cnr1 receptor, but these two classic cannabinoid receptors are functionally not identical as 
demonstrated by the different binding specificity of cannabinoid agonists and antagonists to 
either receptor [14]. Cnr2 is differentially expressed in highly localised regions of the central 











Page 4 of 4 
nervous system and peripheral tissues (Figure 1) and its activation is associated with various 
physiological effects in a discrete and tissue specific manner [15]. 
1.1 Cnr2 expression and function  
The Cnr2 receptor is widely expressed in a number of peripheral tissues including liver, colon, 
pancreas, kidney, myocardium, testis, ovarium, uterus and endothelial cells of various origin 
(Figure 1) where it is implicated in a diverse range of physiological and pathological processes 
(reviewed in [16]). In the immune system, the Cnr2 receptor is highly expressed in T and B 
lymphocytes, monocyte/macrophages, dendritic cells, natural killer cells and neutrophils and a 
number of studies have demonstrated that Cnr2 in these cells is responsible for cannabinoid-
mediated anti-inflammatory and immune-modulating effects [17-20]. Expression of functional 
Cnr2 in peripheral and sensory neurons, particularly nociceptive neurons, confirms the role this 
receptor in the regulation of inflammatory, neuropathic and cancer-related pain [21-23]. In the 
skeleton, Cnr2 is detected in various cells that found within the bone marrow cavity including 
monocytes and macrophages (pre-osteoclasts), in cells that reside on the bone matrix such as 
human and murine osteoclasts (bone resorbing cells), osteoblasts (bone forming cells) and 
their precursors, and in osteocytes embedded within bone matrix [24-29]. The expression levels 
of Cnr2 in osteoblasts, osteoclasts, and osteocytes are significantly higher than the reported for 
Cnr1 [24,27-29]. Furthermore, unlike the Cnr1 receptor, Cnr2 has not been detected in the 
neuronal fibres intervening the skeleton [28,30-32].    
1.2 Cnr2 ligands 
A plethora of endocannabinoids, phytocannabinoids and synthetic ligands bind to Cnr2 receptor 
(Table 1) [33,34]. The endocannabinoid ligand 2-arachidonoylglycerol (2-AG) and N-
arachidonoylethanolamine (anandamide, AEA) are polyunsaturated fatty acids derived from 
hydrolysis of membrane phospholipids on demand (reviewed in [35,36]). Both 
endocannabinoids serve as a precursor to free fatty acids including arachidonic acid and act as 
lipid signalling molecules in a site- and in a time-specific manner (reviewed in [37-39]). The 
action of 2-AG is terminated by enzymatic hydrolysis mediated primarily by the 
monoacylglycerol lipase (MAGL), whereas AEA is mainly metabolised by serine hydrolases 
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fatty acid amide hydrolase (FAAH) [6,11,38,40,41]. Both endocannabinoids bind with high and 
similar affinity to Cnr1 receptor. 2AG act as a full agonist with higher efficacy for Cnr2 receptor 
whereas anandamide has been classified as a partial agonist (Table 1) [42-45]. Cnr2 is also a 
target to a number of the phytocannabinoids including psychotropic ∆9-tetrahydrocannabinol 
(∆9-THC) and non-psychoactive cannabidiol (CBD) (Table 1). The pharmacology of these 
ligands is complex, incompletely understood; a number of studies have reported that most 
phytocannabinoids bind Cnr2 as partial agonist or antagonist depending on the ligand and 
receptor expression levels in the tissue (reviewed in [33,46,47]). Several synthetic 
cannabinoids, mostly structurally similar to phytocannabinoids, such as JWH133, JWH015, 
HU308 [48] and AM1241 act as Cnr2 agonist and/or inverse agonist depending on the tissue 
and species [49] (Table 1). Conversely, Cnr2 selective agents such as AM630 and SR144528 
act as either silent antagonists or as inverse agonists by activating downstream pathways in an 
opposite fashion from Cnr2 agonists [47]. Other synthetic cannabinoid receptor ligands 
including WIN55-212-2 have been reported to equally activate both Cnr2 and Cnr1 [43] 
1.3 Cnr2 structure and signalling 
The Cnr2 receptor is a single peptide seven-transmembrane domain receptor that belongs to 
the family of G protein-coupled receptors (GPR). Cnr2 contains an extracellular glycosilated N-
terminus and an internal C-terminus domain that is coupled to a Gi/o protein (Figure 2) 
[17,50,51]. Cnr2 activation negatively regulates adenylyl cyclase activity [52], causing a 
reduction of intracellular level of cyclic adenosine monophosphate [53,54], that in turn leads to 
the modulation of an array of signalling pathways (Figure 2). Numerous studies have shown 
that Cnr2 selective ligands regulate cell proliferation, differentiation, transformation and death 
by triggering the activation of three major components of the mitogen-activated protein kinase 
(MAPK), namely extracellular signal-regulated kinases1/2 (ERK1/2), p38 and c-Jun N-terminal 
kinases (JNK). Cnr2 was also found to exert apoptosis, necrosis and autophagy through the 
modulations of the Akt-phosphoinositide 3´-kinase (PI3K), AMP-activated kinase (AMPK) and 
ceramide synthesis.  Furthermore, Cnr2 influences cell motility in particular migration and 
invasion by regulating the levels of intracellular calcium, and the expression and activity of 
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adhesion molecules like ICAM or VCAM, matrix metalloproteinases, focal adhesion kinase 
(FAK) and small GTP binding proteins RhoA (Figure 2). Cnr2 activation is also associated with 
inhibition of nuclear factor of kappa B (NFκB) and cyclooxygenase-2 (COX-2) that often leads 
to significant reductions of levels of various pro-inflammatory mediators (reviewed in [53,55-
59]). 
2. Regulation of bone metabolism by Cnr2  
The skeleton is a dynamic and cellulary diverse tissue that is constantly repaired by a complex 
process termed the bone remodelling cycle (Figure 3) (reviewed in [60]). The main cellular 
components of the bone remodelling cycle are osteoblasts (bone forming cells), osteoclasts 
(bone resorbing cells), lining cells and osteocytes, and the action of these cells together play an 
important role in the regulation of bone growth, remodelling, loss and regeneration [61]. The 
action of bone cells is coordinated by mechanical factors and various local and systemic 
mediators including hormones, cytokines and neural peptides [62,63]. The first phase of the 
bone remodelling cycle is bone resorption, during which old bone tissue is removed by the 
multinucleated, highly motile and specialised osteoclasts (Figure 3) [61]. Expansion of the 
osteoclast progenitor pool from hematopoietic cells and the survival and function of mature 
osteoclasts are primarily driven by the osteoblastic-derived cytokines, macrophage colony- 
stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) [64-
66]. Following bone resorption, mononuclear macrophage-like cells remove the remaining 
organic residues that in turn initiate the formation of the cement line which marks the limit of 
bone resorption and joins the new bone to old bone (Figure 3) [61,67,68]. Bone formation is 
triggered by mature osteoclast apoptosis and osteoblasts depositing new bone and matrix 
proteins in the newly resorbed site (Figure 3) [60]. Adipocytes are one of the most abundant cell 
types found in the bone marrow of long bones and a number of studies have shown that their 
differentiation is enhanced in aged skeleton at the expense of osteoblasts [69,70]. In human, 
the processes of bone resorption and bone formation last approximately ten days and three 
months, respectively [71]. The bone formation phase ends with 65% of osteoblasts undergoing 
apoptosis and the remaining osteoblasts are either buried within the newly deposited matrix as 
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osteocytes or converted to lining cells that cover the majority of quiescent bone surface [61]. 
The newly remodelled bone module enters into a resting phase, where quiescent lining cells 
await activation in the next bone remodelling cycle [68].  
2.1 Cnr2 is expressed in the skeleton  
The classical cannabinoid receptors Cnr1 and Cnr2 and their related GPR55 and vanilloid 
receptors are expressed in skeletal tissues. A number of investigators have demonstrated that 
Cnr2 is highly expressed in murine and human bone cells compared to Cnr1 [24,72,73]. The 
expression of Cnr2, at both mRNA and protein levels, was detected in various cells of bone 
marrow origins including M-CSF generated macrophages (pre-osteoclasts), RANKL-stimulated 
multinucleated osteoclasts [27-29] and bone marrow-derived stromal cells [24]. Mature calvarial 
osteoblasts and osteoblast-like cell lines also express Cnr2 [24,73] and possess the machinery 
for the synthesis and metabolism of the Cnr2-selective endocannabinoid 2AG [29,74]. 
Importantly, level of expression of Cnr2 in experimental animals and human has been found to 
be associated with bone growth, bone remodelling and age-related bone loss [24,75]. 
Unpublished work by our group have recently found that Cnr2 in mature calvarial osteoblasts is 
expressed in two different forms most likely representing a glycosylated and a non-glycosylated 
form of Cnr2. Bone marrow and calvarial osteoblasts mainly expressed the non-glycosylated 
form of Cnr2 whereas macrophages and osteoclasts mainly expressed the glycosylated Cnr2 
form (Sophocleous, PhD thesis, University of Edinburgh Research Archive).  
2.2 Protection against age-related bone loss by Cnr 2  
The Cnr2 receptor plays an important role in bone cell activity and bone loss during aging. Ofek 
and colleagues were the first workers to show that aged mice with deficiency in Cnr2 on a 
C57BL/6 genetic background had accelerated age-related trabecular bone loss and cortical 
expansion when compared to wild type littermates [24]. Consistent with these findings, we have 
observed that Cnr2 deficient mice of similar age exhibited accelerated osteoporosis 
characterised by uncoupling of bone resorption from bone formation [73]. This suggests that 
activation of Cnr2 enhances osteoblast and osteoclast activity but causes bone loss due to the 
increase in osteoblast differentiation and bone formation rate in aged animals does not 
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compensate for the excessive bone resorption. Histomorphometric analysis of bones and in 
vitro cultures have confirmed these findings and showed that bone marrow stromal cells and 
calvarial osteoblasts isolated from Cnr2 deficient mice produce less osteoclasts and form less 
bone nodules, indicative of a defect in both osteoclast and osteoblast differentiation [25,73]. 
Moreover, activation of Cnr2 receptors in osteoblasts by endocannabinoids and synthetic 
agonists resulted in a significant increase in the levels of receptor activator of NFκB ligand 
(RANKL) and osteoprotegerin (OPG) production, implicating Cnr2 in the regulation of 
osteoblast-osteoclast crosstalk [76]. Consistently, pharmacological activation of Cnr2 receptor 
signalling using the Cnr2-selective non-psychotropic agonist HU308 protected against bone 
loss induced by oestrogen deficiency by stimulating bone formation rather than inhibiting 
osteoclast number and bone resorption [73]. Collectively, these findings demonstrate that the 
Cnr2 receptor plays a role in bone cell activity and bone metabolism in rodents, which has led 
to the notion that selective therapeutic targeting of the skeletal Cnr2 receptor may be of value 
for the prevention of excessive bone damage associated with a variety of bone diseases.  
2.3 Regulation of peak bone mass by Cnr2 receptor 
We have recently reported that adult mice deficient in Cnr2 were partially protected from 
ovariectomy induced bone loss compared to wild type littermates [73] and Cnr2 knockout mice 
on CD1 background had increased trabecular peak bone mass [77]. These findings are 
contrary to studies in ageing mice but are consistent with pharmacological studies that have 
shown that selective blockade of Cnr2 using the antagonist/inverse agonist AM630 prevented 
ovariectomy induced bone loss [25]. Detailed in vitro and in vivo analysis of bone cell 
differentiation and activity in adult Cnr2 knockout mice and wild type littermates after treatment 
with the Cnr2 inverse agonist AM630 showed that these effects were likely due to a reduction in 
osteoclast number and activity rather than an increase in bone formation. Altogether, these 
results suggest that pharmacological and genetic modulation of Cnr2 affects bone mass 
differentially in young and aged skeleton, while osteoclast inhibition associated with Cnr2 
deficiency in adult mice results in high peak bone mass and prevents bone loss associated with 
oestrogen deficiency. Contrary to this, we did not detect any abnormalities in peak bone mass 
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in young Cnr2 knockout mice in C57Bl’6 background [78] whereas Ofek and colleagues have 
observed a small reduction in bone mass in the same background and at similar age [24,77]. 
Recent work by our group have attributed these differences in skeletal phenotypes that we and 
others have observed to inherent genetic differences between strains and/or a consequence of 
Cnr2 deficiency affecting the expression of large numbers of genes in different strains of mice 
[77,79].  
3. Role of Cnr2 in cancer  
Metastasis to distant sites is a common cause of morbidity and death in advanced cancer 
patients. Although advances in early detection, chemotherapy and radiotherapy have 
significantly reduced death and disease recurrence, acquired resistance to anti-cancer 
therapy and cancer-induced pain still remain major clinical problems. Thus, treatments aimed 
at blocking cancer metastasis and attenuating pain would prove to be beneficial in terms of 
clinical outcomes in cancer patients with advanced disease. All members of the 
endocannabinoid system of ligands, receptors and enzymes have been implicated in tumour 
growth, metastasis and pain. However, the use of cannabis-based therapies in cancer 
patients has been limited and restricted to palliative use [56,80]. In recent years, interest in 
the peripheral Cnr2 as an attractive, druggable target for the treatment of primary cancer, 
metastases and pain has been growing within the cancer research community (reviewed in 
[23,57,81,82]). The use of small-molecule agonists and antagonists to investigate the effects 
of Cnr2 manipulation on tumour growth and pain perception in preclinical mouse models of 
cancer revealed conflicting results. Whilst Cnr2 is highly expressed in various tumours and its 
expression was shown to correlate with poor prognosis [83,84], both pro- and anti-tumour 
effects have been associated with its activation. Furthermore, the mechanisms by which Cnr2 
exerts these effects vary between tumour cell types, animal models and cancers [56,83-90]. 
This review highlights the role of Cnr2 in skeletal tumour growth, bone remodelling and pain 
perception, and focuses on the effects of various Cnr2 selective ligands that have been 
reported to alleviate skeletal complications associated with cancer.  
3.1 Role of Cnr2 in cancer induced bone disease  
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Cancer induced bone disease (CIBD) is common in patients with primary bone cancer, bone 
metastases and those who are receiving chemotherapy [91-95]. Excluding haematological 
malignancies, malignant primary bone tumours such as sarcomas are rare and represent less 
than 0.2% of all cancers in the developed world [96], whereas secondary bone metastases 
are relatively more common and constitute more than 99% of bone tumours [97]. Solid 
tumours of breast and prostate origin that develop metastatic potential have a remarkably 
high rate of metastasis to bone, with an incidence of 80% and 70% respectively (reviewed in 
[91,92,98]).  In contrast, only 30% of patients with lung, colon, stomach, bladder, uterus, 
rectum, thyroid, or kidney carcinoma develop cancer associated bone disease [99]. Clinical 
complications associated with CIBD in advanced cancer patients are life debilitating and 
include severe bone pain, restricted mobility, pathological fracture, hypercalcemia and nerve 
compression [91,100]. CIBD is virtually incurable and life expectancy for patients with the 
condition is low, variable and depends on the primary tumour type, site and number of bone 
metastases [101,102]. 
CIBD is mainly caused by abnormal and uncontrolled growth of cancer cells in bone that 
progressively alters bone cell activity and turnover and ultimately lead to excessive bone loss 
(Figure 3). Osteotropic cancer cells, whether of bone origin or metastatic, are incapable of 
causing bone resorption but these cells secret various osteolytic and osteoblastic factors 
thereby causing bone lesions [95,103]. Tumour-derived factors such us parathyroid hormone-
related peptide (PTHrP), transforming growth factor beta (TGF-β), prostaglandin E2 (PGE2), 
bone morphogenetic protein (BMPs), platelet derived growth factors (PDGF), endothelin-1 
(ET-1), insulin-like growth factor 1 (IGF1), vascular endothelial growth factor (VEGF) and 
interleukins directly or indirectly disrupt the normal balance between osteoblasts and 
osteoclasts, increasing osteoblast differentiation and activity, resulting in excessive osteoclast 
formation and bone resorption (reviewed in [104-106]). Cancer cells in bone (i.e. osteotropic 
cells) are also capable of stimulating osteoclast activity directly or through their ability to 
instruct immune cells or osteoblasts to release osteolytic factors such as IL-11, IL-6, IL-8, IL-
17, PTHrP, tumour necrosis factor –α (TNF- α), VEGF, matrix metalloproteinases (MMPs), 
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and RANKL (reviewed in [105,107-110]). Bone resorption by osteoclasts releases factors 
from the bone matrix such as TGF-β and IGF-1 that further enhance tumour growth and bone 
destruction [111,112]. Bone metastases are classified according to the radiological 
appearance as osteolytic, caused by an excessive osteoclastic bone resorption or 
osteoblastic, characterized by an excessive and uncontrolled bone formation [105,107,113]. 
Current bone targeted therapies strongly inhibit osteoclast formation and bone resorption but 
they have no significant, direct impact in skeletal tumour burden and CIBD-related bone pain 
[99,100,114]. This necessitates the need to identify additional therapeutic strategies that - 
alone or in combination with conventional anti-cancer therapies - reduce tumour skeletal 
burden, prevent bone metastases, halt recurrence, and attenuate pain in advanced cancer 
patients with CIBD.  
The endocannabinoid system is implicated in pain perception and tumour growth, and 
pharmacological and genetic manipulation of Cnr2 has been found to reduce the progression 
of CIBD. To date, three distinct but not exclusive mechanisms have been described for Cnr2-
mediated anti-cancer and osteo-protection. First, agents that activate and block Cnr2 directly 
act on cancer cells and induce apoptotic and necrotic cell death. Secondly, by inhibiting 
osteoclast formation and bone resorption, Cnr2 selective ligands reduce osteolysis and bone 
damage. Thirdly, activation of Cnr2 has been found to attenuate cancer-induced bone pain by 
(a) directly targeting various pain related pathways and/or (b) indirectly inhibiting bone 
damage. 
3.1.1 Regulation of skeletal tumour cell growth by Cnr2  
A large body of evidence indicates that modulation of Cnr2 receptor impairs the progression 
and growth of various tumours and cell lines such as breast, prostate and lung cancer cells 
which are all known to metastasize to bone [81,82,85]. Although the mechanisms 
downstream of Cnr2 responsible for these effects are not completely understood, it is evident 
that Cnr2 selective ligands inhibit cancer cell proliferation [115-119] and induce apoptosis-
mediated cell death in vitro and in vivo [89,90,120]. Various investigators have observed a 
significant reduction of cancer cell invasion and metastases following treatment to Cnr2 
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selective ligands [121-123]. These effects were mainly attributed to inhibition of the proteolytic 
matrix metalloproteinases MMP2 and MMP9, and the increase in the expression of their 
inhibitor TIMP-1 [83,123-126]. Activation of Cnr2 receptor in tumour cells was also found to 
be associated with significant inhibition of tumour angiogenesis due to the reduction of 
tumour-derived vascular endothelial growth factor (VEGF) [118,127]. Autocrine inhibition of 
VEGF and other tumour-derived mediators such as angiopoietin 2 by Cnr2 activation reduces 
tumour cell motility and the support of vascular endothelial cells present in the tumour 
microenvironment to tumour cells [128]. Altogether, these findings indicate that Cnr2 plays a 
significant role in tumour cell growth and motility. 
The fact that Cnr2 is highly expressed in bone cells compared to Cnr1 has led a number of 
investigators to pursue Cnr2 as a candidate therapeutic target for the treatment of CIBD. One 
of the key pathological features of CIBD is skeletal tumour burden due to excessive 
proliferation and increased survival of tumour cells in bone [129]. However, thus far the 
evidence that targeting the Cnr2 receptor could be of value in the reduction of skeletal tumour 
growth is confined to limited in vitro and preclinical studies carried out in mouse models of 
breast cancer- and osteosarcoma-induced CIBD. Lozano-Ondoua and colleagues were the 
first investigators to report that pharmacological modulation of Cnr2, using Cnr2 selective 
agonist JWH015, reduced the number of the breast cancer cell line 66.1 in the intramedullary 
cavity of mice after intra-femoral injection [130]. Further in vitro studies using the same cell 
line confirmed the anti-proliferative effects of this compound and showed that JWH015 and 
AM1241 – which have been reported to act as Cnr2 agonist and inverse agonist [49,131,132] 
– induced 66.1 cell apoptosis at microMolar concentrations. In broad agreement with these 
findings, we have recently observed that the Cnr2 selective agonists JWH133 and HU308 
reduced the proliferation of naive and osteotropic mouse 4T1 and human MDA-MB-231 
breast cancer cells in a concentration dependent manner with an IC50 at a microMolar range 
[76]. Interestingly, both agents were more active and exerted more anti-proliferative effects on 
the osteotropic mouse 4T1 and human MDA-MB-231 cells when compared to their naïve, 
parental clones [76]. This suggests that osteotropic cancer cells are more sensitive to Cnr2 
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activation but further work is needed. Work performed by Hsu et al. reported that the 
endocannabinoid and non-selective Cnr1/2 agonist anandamide induced osteosarcoma cell 
death via a mechanism mediated by p38 MAPK phosphorylation and caspase-3 activation, 
consistent with apoptosis-mediated cell death [133]. Further studies in osteosarcoma by 
Notaro et al. showed that the synthetic and non-selective Cnr1/2 agonist WIN55,212-2 
induced morphological changes in osteosarcoma cells in vitro consistent with autophagy-
mediated cell death but failed to induce apoptotic death under these conditions [134]. This 
finding was not surprising because it was previously reported that exposure to cannabinoid 
ligands induces autophagy in other cancer cell lines [90,135-137]. The authors of this study 
also demonstrated that WIN55,212-2 sensitized osteosarcoma cells to apoptosis and 
significantly enhanced the antitumor activity of TRAIL [134] and Adriamycin [138]. In addition, 
emerging evidence suggests that targeting Cnr2 could be of value in the prevention of tumour 
cells homing to bone. Nasser et al. reported that activation of Cnr2 reduces breast cancer 
progression and metastasis via a mechanism mediated by inhibition of chemokine ligand 12 
(CXCL12) [139], one of the key factors implicated in the progression of bone metastasis 
(reviewed in [140-142]). However, the authors of this article have not directly investigated the 
effects of pharmacological modulation of Cnr2 in models of bone metastases. GPR55 
receptors which were found to be overexpressed in a wide variety of cancer cell lines and 
human malignant tumors [143], are implicated in the modulation  of cancer cell fate 
[82,144,145]. Bearing in mind that both Cnr2 and GPR55 are highly expressed in the skeleton 
[25,73,146], it is tempting to speculate that Cnr2-GPR55 heterodimers [147,148] may also 
play a role in tumour growth in bone and agents that target both receptors may be of value in 
the reduction of skeletal tumour burden.  
3.1.2 Regulation of osteolysis by Cnr2  
The major clinical complication associated with CIBD in advanced cancer patients is 
osteolytic bone destruction associated with enhanced osteoclast formation, survival and 
function. Tumour cells are known to release a variety of factors that directly stimulate 
osteoclastogenesis and indirectly enhance the ability of osteoblasts and immune cells such 
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as T lymphocytes and dendritic cells to support osteoclastogenesis and to increase bone loss 
[107,149,150] (Figure 4). We and others have found that pharmacological modulation and 
genetic inactivation of Cnr2 influence the ability of tumour cells to cause osteolysis and to 
influence osteoblast – osteoclast crosstalk (Figure 5). Lozano-Ondoua et al. have found that 
the Cnr2 selective, non-psychoactive JWH015 reduced cancer-induce bone loss and cortical 
fracture in a murine bone cancer model of breast cancer [130,151]. Histological examination 
of longs bone from these mice revealed that this compound reduced skeletal tumour growth 
and reduced the level of the bone markers collagen type 1 cross-linked C-telopeptide (CTX), 
TRAcP5b and osteocalcin, indicative of significant inhibition of bone turnover. Further work by 
the same group albeit in a different mouse model of bone cancer has confirmed these 
findings and showed that AM1241 reduced sarcoma-induced osteolytic bone damage and 
fracture [151]. Whilst it is evident that these agents reduced cancer induced bone damage in 
the mouse models described, it is unclear whether these protective effects were due to 
reduction of skeletal tumour growth and/or osteoclast inhibition or stimulation of osteoblast 
differentiation as previously reported in animals models of osteoporosis [24,73]. It is also 
unclear if the agents tested in these studies act as partial/full inverse agonists or antagonists 
at Cnr2 and/or any other related receptor. 
In recent studies carried out in our laboratories, we have examined the role of the skeletal 
Cnr2 receptor in the regulation of breast cancer-induced bone cell activity and osteolysis [76]. 
In our studies, we showed that mouse and human breast cancer cells and their derived 
factors enhanced RANKL-induced osteoclast formation and bone resorption in vitro and these 
effects were significantly enhanced in the presence of the Cnr2 selective agonists HU308 and 
JWH133 at concentration below 1µM and were inhibited by the Cnr2 selective inverse 
agonists AM630 or in cultures of pre-osteoclasts generated from Cnr2 deficient mice [76]. 
Then, we went on to demonstrate that pharmacological activation of Cnr2 in osteoblasts in 
vitro significantly enhanced the ability of osteotropic cancer cells to stimulate osteoclast 
formation. In vivo and ex vivo studies confirmed these findings and showed that activation of 
Cnr2 exacerbated breast cancer-induced osteolysis and bone loss by stimulating osteoclast 
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formation whereas genetic inactivation and pharmacological blockage of Cnr2 was inhibitory 
[76]. Mechanistic studies in cancer and bone cells revealed that Cnr2 activation regulates 
breast cancer cell – osteoblast – osteoclast differentiation and crosstalk by (a) enhancing 
breast cancer-induced RANKL/OPG ratio in osteoblasts and (b) breast cancer-related PI3-Akt 
activation in pre-osteoclasts. It is important to note that these effects were obtained at 
concentrations that failed to affect the viability and proliferation of osteoblasts, pre-osteoclasts 
and breast cancer cells, thereby excluding toxic effects. Evidence to date suggests that Cnr2 
activation enhances bone cell activity and exacerbates breast cancer-induced osteolysis by a 
direct effect on bone cells, namely osteoblasts and osteoclasts (Figure 5). Thus, inhibition of 
Cnr2 receptor signaling under these conditions may have a potential therapeutic effect 
against cancer induced bone loss. It is important to note that these findings apply only to the 
bone cell-autonomous contribution of Cnr2 and do not exclude the strong inhibitory effects of 
Cnr2 ligands on tumour cell growth and proliferation in vitro and in vivo previously described 
by us [76] and other investigators [130,151].  
3.1.3 Regulation of cancer-induced bone pain by Cnr 2  
Primary bone tumours and bone metastases are characterized by a debilitating pain 
(reviewed in [152,153]). The bone-min ralized matrix is densely innervated by sensory 
neurons and both Cnr1 and Cnr2 have been found to be expressed in peripheral neurons and 
in the immune cells such as microglia in the spinal cord  (reviewed in [15]). Bone-infiltrating 
tumour cells secrete pro-inflammatory cytokines and factors, namely nerve growth factor 
(NGF) and endothelin 1 that are known to enhance pain perception (reviewed in [154]). 
Furthermore, a number of studies have shown that tumour cell growth and expansion in bone 
induces nerve compression and injury that in turn enhances cancer-induced bone pain [155-
157]. Furthermore, pain, pro-angiogenic and pro-inflammatory mediators including IL-1β, 
TNFα and IL-6 produced by tumour-associated macrophages and monocytes play an 
important role in the pathogenesis of cancer-induced bone pain [154,158-160]. These 
findings together suggest that agents that suppress tumour growth, reduce inflammation, 











Page 16 of 16 
inhibit osteoclastic bone damage and protect against nerve injury may be of value for the 
treatment pain associated with CIBD. 
The endocannabinoid system is implicated in inflammatory, neuropathic and cancer-induced 
pain (reviewed in [23,151,161]). Secretion of endocannabinoids and expression of Cnr1 and 
Cnr2 receptors are upregulated in models of chronic pain [162]. A number of studies have 
shown that administration of phyto or synthetic cannabinoid receptor agonists exerted strong 
anti-nociceptive and anti-hyperalgesic effects in animal models of neuropathic [163] and 
inflammatory pain [164]. The clinical cannabis-based agent Sativex – which is known to 
activate both Cnr1 and Cnr2 - attenuated cancer-induced bone pain [161,165]. While these 
findings were encouraging, the adverse psychoactive effects caused by activation of 
cannabinoid receptors, in particular Cnr1, in the brain may limit the development of these 
agents for cancer treatment. This and the fact that long-term use of analgesics such as 
opiates is often associated with excessive bone loss [166] encouraged the development and 
testing of selective Cnr2 for the reduction of cancer-induced pain [23,167-171].  
In 2010, Lozano and colleagues have reported that the Cnr2 selective ligand AM1241 
reduced spontaneous and movement-evoked pain in a mouse model of sarcoma [151]. Later 
work by the same group showed that the Cnr2 selective JWH015 reduced spontaneous 
flinching and guarding in mice following intra-femoral injection of breast cancer cells [130], 
indicating a strong local analgesic effect in the model described. Recent work by Khasabova 
et al. confirmed the involvement of Cnr2 in the regulation of pain perception in cancer and 
showed that increased levels of the endocannabinoid 2AG by pharmacological inhibition of 
MAGL reduced tumour-evoked bone pain via a mechanism dependent on Cnr2 activation 
[172]. On the other hand, mechanistic studies showed that activation of Cnr2 signalling in 
immune cells and microglia reduced the levels of various pro-inflammatory mediators 
implicated in the regulation of pain [151,169,173,174]. Treatment with Cnr2 receptor agonists 
has also been found to enhance the release of endogenous opioid peptides that may 
contribute to the anti-nociception associated with Cnr2 activation [175,176]. Together, these 
findings suggest that selective targeting of the peripheral Cnr2 may have translational 
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benefits in identifying non-psychoactive, analgesic agents for the treatment of cancer induced 
pain.  
4. Challenges and future direction  
The majority of deaths from cancer following the failure of conventional therapies are a result 
of metastases. Although advances in early detection, chemotherapy and radiotherapy have 
significantly reduced cancer-related death, disease recurrence and acquired resistance to 
conventional therapies still remain major clinical problems. Cancer associated bone disease 
and pain are serious clinical complications of metastatic cancer that are often inadequately 
managed in patients with advanced disease [91,177,178]. To date, treatment of CIBD has 
focused on anti-osteoclast agents, such as bisphosphonates and Denosumab [129], which 
are known to reduce skeletal complications in patients with osteolytic metastatic disease but 
they are incompletely effective and lack a direct, significant effect on bone pain [179-182]. 
Thus, there is a need to identify additional therapeutic strategies that either alone or in 
combination with conventional anti-cancer agents suppress bone metastasis, reduce bone 
damage, halt recurrence, and attenuate pain in cancer patients with CIBD.  
Endocannabinoids and their receptors play an important role in the regulation of 
tumorigenesis, metastasis and pain [6-10]. There has been increasing interest in targeting of 
the cannabinoid system in the treatment of cancer. Cannabinoid receptor agonists exert anti-
emetic properties and have been used for the treatment of nausea and vomiting associated 
with cancer chemotherapy [57,183]. Cannabinoid receptor ligands also display analgesic 
effects, muscle relaxant properties and mood–elevating properties with a number of these 
ligands widely studied in patients with neuropathic and metastatic pain [57,183]. Cnr1 and 
Cnr2 are expressed in various tumours, and cannabinoid ligands reported to exert both 
stimulatory and inhibitory effects on cancer cell proliferation in vitro and tumour progression in 
vivo (Reviewed in [57,183]). In the last decade, the peripheral Cnr2 receptor has emerged as 
an attractive target for developing anti-cancer drugs. The most important rationale for the 
focus on Cnr2, is that ligands that selectively bind to Cnr2 would be expected to elicit less 
adverse psychoactive effects and tolerance associated with cannabinoid-based therapy 
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[23,176,184]. Therefore future studies are needed to compare the effects of cannabis clinical 
extracts such as Sativex and selective Cnr2 ligands on cancer metastasis. Systemic and 
prolonged treatment with selective Cnr2 agents may still cause adverse effects due to 
activation of Cnr2 and other opioid receptors in the peripheral [176] and albeit highly unlikely 
in the central nervous system. Thus, the development and testing of tumour-selective Cnr2 
ligands that do not cross the blood-brain barrier would be of great benefit in eliminating the 
possibility of these adverse effects occurring. Such studies are timely and if successful, will 
(A) pave the way for future research that will advance our knowledge about the basic 
mechanism(s) by which the endocannabinoid system regulate cancer metastasis, (B) 
stimulate the research and development of a safer cannabis-based therapy for the treatment 
of metastatic cancer, (C) address a huge unmet clinical need, as metastasis is a major 
problem affecting advanced cancer patients and (D) provide policy makers with powerful tools 
to assess the science and therapeutic potential of cannabinoid-based therapy. 
The Cnr2 receptor is implicated in the regulation of tumour – bone cell interactions and there 
are four main strategies that could potentially be pursued for targeting Cnr2 for the treatment 
of cancer associated bone disease; 1) reduction of metastasis to bone, 2) inhibition of tumour 
growth in bone, 3) suppression of cancer-induced osteoclast formation and osteolysis, and 4) 
stimulation of bone formation to aid with bone regeneration. Studies to date have indicated 
that agents that target Cnr2 in the skeleton have potential efficacy in the reduction of cancer-
induced osteolysis and pain. However, the role of Cnr2 in the development and progression 
of bone metastases is yet not fully understood and very little research has so far been 
conducted on the direct effects of Cnr2 selective ligands on skeletal tumour growth, even 
though Cnr2 ligands have been studied as possible anti-tumour agents in primary cancers 
[183]. Furthermore, Cnr2 receptor plays an important role in bone formation but recent 
studies have failed to address the effects of Cnr2 selective ligands on osteoblast function in 
metastatic cancer. There are also other numerous unanswered questions and key issues that 
may limit the usefulness of Cnr2 selective agents as bone sparing drugs in cancer patients. 
For example, studies to date, including those conducted by our group [76], have failed to 
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address whether exposure to high concentrations and doses of Cnr2 selective ligands exert a 
compensatory expression and activity of other cannabinoids and/or their related receptors 
such as opioid and dopamine, which are known to dimerise with cannabinoid receptors 
[185,186]. In addition to Cnr2, other cannabinoid receptors, in particular Cnr1 and related 
receptors including GPR55, opioid and vanilloid receptors are implicated in the regulation of 
normal and cancer associated bone remodelling. Therefore more comprehensive studies in 
genetically modified animals that lack cannabinoid receptors and enzymes are needed to fully 
address their roles. Future studies should also take into account that pharmacological 
activation or antagonism of Cnr2 may lead to a complex reorganization of the fine-tuned 
endocannabinoid system that in turn result in a shift in the level of endocannabinoid balance, 
causing a transactivation of other related receptors such as Cnr1, GPR55 and vanilloid 
receptors which are known to influence bone cell activity and function [28,187]. The discovery 
of key intracellular pathways, particularly pivotal cytokine and immune cell receptors 
implicated in the regulation of bone – immune – cancer interactions may facilitate the advent 
of a new phase of Cnr2-based therapy for the treatment of cancer induced bone disease. 
Inhibition of elements involved in Cnr2 signalling has the potential to enhance the efficacy of 
radiotherapy and chemotherapy. The increase in our knowledge of these challenging and 
“thorny” issues may aid with the design of a better and more effective therapeutic strategy to 
selectively target Cnr2 signalling to suppress bone damage, alleviate bone pain and reduce 
skeletal tumour burden. 
5. Conclusion 
Targeting Cnr2 receptor has been a hot topic in cancer pain treatment in the last decades. A 
number of preclinical studies have demonstrated that the skeletal Cnr2 receptor plays a role 
in the regulation of tumour – bone cell interactions and preclinical studies showed that 
pharmacological targeting of Cnr2 are effective in reducing skeletal tumour burden, inhibiting 
osteolysis and attenuating bone pain in animal models of osteolytic bone disease. 
Notwithstanding the inherent limitations of the preclinical models used in these studies and 
the colossal challenges associated with the development and testing of peripherally-acting, 











Page 20 of 20 
Cnr2-selective compounds, the present data indicate that small molecule ligands to Cnr2 
could be of value for the treatment of skeletal complications associated with cancer. Future 
research and development of Cnr2-selective ligands will stimulate the development of safer 
cannabis-based therapy for the treatment of cancer. Thus, offering the prospect of identifying 
these agents, as novel, alternative to cannabis herbal extracts for the treatment of advanced 
cancer patients. 
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Figure legends  
Figure. 1. Type 2 cannabinoid receptor expression.  Type 2 cannabinoid receptor (Cnr2) is 
detected in a variety of tissues but it is predominantly expressed in cells of the immune 
system, localized area of the central nervous system and in bone cells. 
Figure 2. The signal transduction pathways associat ed with type 2 cannabinoid 
receptor activation in cancer and bone cells.  The majority of cancer-related effects 
associated with Cnr2 receptor are mediated by Gi/o-dependent activation of adenylyl cyclase 
activity (AC) and cAMP in cancer and host cells in tumour microenvironment. Reduced levels 
of intracellular cAMP levels prevent activation of transcription factors CREB, nuclear factor 
kappa B (NFκB) and AP1 by a PKA-dependent mechanism culminating in inhibition of 
expression of related genes. PKA also modulates the FAK/SRC/RHOA pathway and COX 
that regulate migration/invasion and angiogenesis. Ligand-induced activation of Cnr2 and 
Gi/o regulates the activity and expression of various proteins from the MAPK family including 
p38, JNK, ERK, PI3K/Akt and stimulates ceramide synthesis de novo in cancer cells, leading 
to activation of transcription factors involved in cell proliferation, cell-cycle progression and 
apoptosis- or autophagy-mediated cell death. Activation of Cnr2-mediated Akt in bone cells 
contributes to breast cancer induced osteoclast formation and osteolysis. Activation of Cnr2 
receptor in cancer cells has been recently associated with the modulation of calcium and 
potassium channels and phospholipase C (PLC)-mediated release of calcium from the 
endoplasmic reticulum, leading to activation of NFATc1 transcription factor. Abbreviations; 
AC, adenylyl cyclase: cAMP, cyclic adenosine monophosphate; Gi, inhibitory class of G 
protein; PKA, protein kinase A; cAMP-dependent protein chinase; JNK, jun N- terminal 
kinase; p38, p38 mitogen-activated protein kinase; ERK, extracellular receptor kinase; PI3K, 
phosphoinositide 3-kinase; Akt, protein kinase B; mTORC, mammalian target of rapamycin 
complex 1; FAK, focal adhesion kinase; Src, sarcoma tyrosine kinase; RhoA, Ras homolog 
gene family, member A; COX-2, cycloxigenase-2;; CXCR4, chemokine receptor 4; CXCL12, 
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chemokine ligand 12; VEGF, vascular endothelial growth factor; MMP matrix 
metalloproteinase; PGE2, prostaglandin E2. 
Figure 3. The bone remodelling cycle during adulthood (a) and  ageing (b).  Following 
mechanical stress or micro-damage, osteoclast precursors and mature osteoclasts initiate 
bone resorption by migrating to the site to be remodeled. The next major stage of the 
remodelling cycle involves the recruitment of osteoblast precursors to the site of resorption 
and deposition of new bone. Remaining osteoblasts are either buried within the newly 
deposited matrix as osteocytes or converted to lining cells that cover the majority of quiescent 
bone surface. Significant accumulation of adipocytes in the bone marrow cavity is often 
observed in aged skeleton (b). The newly remodeled bone enters into resting phase, where 
the quiescent lining cells await to be activated. oB, osteoblasts; oC, osteoclasts: adipo, 
adipocytes. 
Figure 4. The bone remodelling cycle during osteoly tic and osteoblastic cancer 
induced bone disease. (a) Malignant tumour cells that colonize bone cause bone osteolytic 
lesions by secreting factors that act directly, on osteoclasts and their precursors, or indirectly, 
on osteoblasts, thereby enhancing osteoclast formation and activity. As a consequence of 
increased resorption by osteoclasts, released bone-derived factors further enhance tumour 
cell proliferation, thereby exacerbating osteolytic bone loss. (b) Osteoblastic bone lesions are 
caused by excessive stimulation of osteoblast proliferation, differentiation and function by 
cancer cells that often leads to the formation of abnormal and disorganized new bone. This 
phase is often followed by an increase in osteoclast number and bone resorption. Parathyroid 
hormone-related peptide (PTHrP), tumor necrosis factor –alpha (TNF-α), TGF-β, 
prostaglandin E2 (PGE2), bone morphogenetic protein (BMPs), platelet derived growth 
factors (PDGF), endothelin-1 (ET-1), insulin-like growth factor 1 (IGF1), vascular endothelial 
growth factor (VEGF) and interleukins (ILs), matrix metalloproteinases (MMPs). 
Figure 5. Current model of regulation of cancer – b one cell interactions by Cnr2.  
Pharmacological activation of Cnr2 in vivo inhibits osteoclast number, increase osteoblast 
number, reduces osteolysis and attenuates bone pain in mouse preclinical models of cancer. 
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In vitro, a biphasic effect of Cnr2 activation has been observed. Low concentrations of Cnr2 
agonists increase osteoclast formation and activity without affecting tumour cell proliferation, 
whereas high concentrations exert anti-resorptive and anti-tumour effects. Abbreviations; oB, 
osteoblasts; oC, osteoclasts, Tm, cancer cells, nM, nano-Molar, µM, microMolar. 
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Table 1. The role of cannabinoid receptor ligands in the Cnr2-mediated regulation of osteoclast, osteoblast and cancer in vitro and in vivo. 
   Bone metabolism Cancer 
 



















AEA Cnr2/Cnr1/GPR55 ↑ ↑ ↑ ↓↓ - ↓ 






Phytocannabinoids ∆9-THC Cnr2/Cnr1 - - - ↓↓↑↑ - ↓ 
 Cannabidiol Cnr2/Cnr1/ TRPV1 ↑ ↓↓ - ↓↓ - ↓ 
HU308 Cnr2 ↑↓↓ ↓ ↑↑ ↑↓ ↑* - 




JWH139 Cnr2 - - - ↓ - - 
 JWH015 Cnr2 - ↑ ↑ ↓↓ ↓ ↓ 
 AM1241 Cnr2 - - - ↓ ↓ ↓ 
 WIN55,212-2 Cnr2/Cnr1 - - ↑ ↓↓ - ↓ 
 CP55,940 Cnr2/Cnr1 ↑↓ ↑ ↑ ↓ - ↓ 
Antagonists/ AM630 Cnr2 ↓↓↑ ↓ - - ↓* - 
Inverse agonist SR144528 Cnr2 ↓ ↓ - - - - 
The data presented in this table are assembled from references [21,24,25,73,76,81,85,188]. ↑, increase; ↓, decrease; -, non tested:* ex-vivo models. 
Black and red arrows denote in vitro and in vivo data, respectively. Abbreviations; Oc., osteoclast, Ob., osteoblast, Tm. Tumour cell. 
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